Properties of antiviral agents. 1.
D000212:Acyclovir / Q000009:adverse effects / Q000494:pharmacology; D000998:Antiviral Agents / Q000009:adverse effects / Q000494:pharmacology*; D001973:Bromodeoxyuridine / Q000031:analogs & derivatives / Q000494:pharmacology; D005069:Evaluation Studies as Topic; D017245:Foscarnet; D006564:Herpesviridae / Q000187:drug effects; D006801:Humans; D007065:Idoxuridine / Q000009:adverse effects / Q000494:pharmacology; D010746:Phosphonoacetic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology; D014271:Trifluridine / Q000009:adverse effects / Q000494:pharmacology; D014740:Vidarabine / Q000009:adverse effects / Q000494:pharmacology; D014780:Viruses / Q000187:drug effects
D000998:Antiviral Agents; C020235:brivudine; D017245:Foscarnet; D014740:Vidarabine; D001973:Bromodeoxyuridine; D007065:Idoxuridine; D010746:Phosphonoacetic Acid; D014271:Trifluridine; D000212:Acyclovir